

Editorials

Digital therapeutics for remote symptom monitoring and management in cancer care: the current and future state
E. Basch

Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy

I. F. Tannock, G. Bouche, D. A. Goldstein, Y. Goto, A. S. Lichter, K. Prabhash, P. Ranganathan, L. B. Saltz, G. S. Sonke, G. W. Strohbehn, R. von Moos & M. J. Ratain

Special Article

ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

P. Tarantino, G. Viale, M. F. Press, X. Hu, F. Penault-Llorca, A. Bardia, A. Batistatou, H. J. Burstein, L. A. Carey, J. Cortes, C. Denkert, V. Diéras, W. Jacot, A. K. Koutras, A. Lebeau, S. Loibl, S. Modi, M. F. Mosele, E. Provenzano, G. Pruneri, J. S. Reis-Filho, F. Rojo, R. Salgado, P. Schmid, S. J. Schnitt, S. M. Tolaney, D. Trapani, A. Vincent-Salomon, A. C. Wolff, G. Pentheroudakis, F. André & G. Curigliano

Original Articles

Breast tumors

Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2+ metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial
N. Harbeck, P. A. Fasching, R. Wuerstlein, T. Degenhardt, D. Lüftner, R. E. Kates, J. Schumacher, P. Räh, O. Hoffmann, R. Lorenz, T. Decker, M. Reinisch, T. Göhler, P. Staib, O. Gluz, T. Schinköthe & M. Schmidt, on behalf of the AGO-B WSG PreCycle investigators

635 Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study

M. Oliveira, C. Falato, J. M. Cejalvo, M. Margelí Vila, P. Tolosa, F. J. Salvador-Bofill, J. Cruz, M. Arumi, A. M. Luna, J. A. Guerra, M. Vidal, O. Martínez-Sáez, L. Paré, B. González-Farré, E. Sanfeliu, E. Ciruelos, M. Espinosa-Bravo, S. Pernas, Y. Izarzugaza, S. Esker, P.-D. Fan, P. Parul, A. Santhanagopal, D. Sellami, G. Villacampa, J. M. Ferrero-Cafiero, T. Pascual & A. Prat

670

Gynecological tumors

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

I. Ray-Coquard, A. Leary, S. Pignata, C. Cropet, A. González-Martín, C. Marth, S. Nagao, I. Vergote, N. Colombo, J. Mäenpää, F. Selle, J. Sehouli, D. Lorusso, E. M. Guerra Alia, G. Bogner, H. Yoshida, C. Lefevre-Plesse, P. Buderath, A. M. Mosconi, A. Lortholary, A. Burges, J. Medioni, A. El-Balat, M. Rodrigues, T.-W. Park-Simon, C. Dubot, D. Denschlag, B. You, E. Pujade-Lauraine & P. Harter, for the PAOLA-1/ENGOT-ov25 investigators

681

Onco-Immunology

IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications

M. Burotto, Z. Zvirbule, A. Mochalova, Y. Runglodvatana, L. Herraes-Baranda, S. N. Liu, P. Chan, E. Shearer-Kang, X. Liu, N. Tosti, J. A. Zanghi, B. Leutgeb & E. Felip

660

693

Gastrointestinal tumors

Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability

T. Ratovomanana, R. Nicolle, R. Cohen, A. Diehl, A. Siret, Q. Letourneur, O. Buhard, A. Perrier, E. Guillermin, F. Coulet, P. Cervera, P. Benusiglio, K. Labrèche, R. Colle, A. Collura, E. Despras, P. Le Rouzic, F. Renaud, J. Cros, A. Alentorn, M. Touat, M. Ayadi, P. Bourgoin, C. Prunier, C. Tournigand, C. de la Fouchardière, D. Tougeron, V. Jonchère, J. Bennouna, A. de Reynies, J.-F. Fléjou, M. Svrcek, T. André & A. Duval

703

Head and neck tumors

A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer

A. J. Rosenberg, C.-Y. Liao, T. Karrison, J. A. de Souza, F. P. Worden, B. Libao, M. K. Krzyzanowska, D. N. Hayes, E. Winquist, V. Saloura, K. Prescott, V. M. Villaflor, T. Y. Seiwert, R. B. Schechter, W. M. Stadler, E. E. W. Cohen & E. E. Vokes

714

Letter to the Editor

Costs per event averted in the neoadjuvant and adjuvant settings of early triple negative breast cancer

T. Olivier & V. Prasad

723

Corrigendum

Corrigendum to “Exploring the role of accessory biomarkers TMB, STK11, KEAP1, and KRAS in non-small-cell lung cancer: confused, but on a much higher level” [Annals of Oncology 34 (2023) 327-332]

L. Bazhenova

725

Erratum

Erratum to “P-309 In vitro drug screening of patient-specific tumoroids to predict chemotherapeutic treatment response in pancreatic ductal adenocarcinoma: An interim analysis” [Annals of Oncology 33 suppl. 4 (2022) S355]

C. Nitschke, C. Phan, L. Konczalla, M. Goetz, M. Sinn, O. Thastrup, J. Izbicki, F. Uzunoglu & T. Sturmheit

727